Class IIOngoingD-0653-2026
Drug recall · July 8, 2026
IMULDOSA recall
Why: Lack of assurance of Sterility:
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
IMULDOSA, (ustekinumab-srlf) Injection, 130 mg/26 mL (5mg/mL), Rx only, Single dose vial, Manufactured by Accord BioPharma Inc., 8041 Arco corporate Drive, Suite 200, Raleigh, NC 27617, USA, Manufactured at: Catalent Indiana, LLC, 1300 S. Patterson Drive, Bloomington, IN 47403, USA, NDC 69448-019-26.
- Lots / codes
Lot # 004L24A, Exp Date: 02/19/2027.
- Quantity
- 326 vials
- Company
- Accord Biopharma Inc, Raleigh, NC
- Distribution
- US Nationwide.
- Initiated
- June 10, 2026 · Voluntary: Firm initiated
- Classified
- June 29, 2026
- Reported
- July 8, 2026
- How notified
- Letter
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.